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treatment with latanoprost (p < 0.001); and the existence of oph-
thalmologic comorbidities, also with a 3-times higher hazard of
treatment withdrawal in patients that suffer an additional oph-
thalmic pathology (p < 0.007). The main reasons for treatment
drop-out were lack of efﬁcacy and the existence of intolerance
and/or adverse events, numerically superiors in the bimatoprost
and travoprost group. CONCLUSION: Latanoprost shows a
higher persistence degree vs. travoprost and bimatoprost in
routine clinical practice.
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OBJECTIVES: This controlled cross-sectional observational
study was conducted in 4 EU countries and Canada to assess the
burden of bilateral neovascular AMD on patient-reported func-
tioning and health resource utilization (HRU). METHODS: Of
the total 401 bilateral neovascular AMD patients and 471 elderly
non-AMD (control) subjects, 87 and 92 respectively were
French. After recording of Demographic and treatment data,
National Eye Institute Visual Function Questionnaire (NEI VFQ-
25), EuroQol (EQ-5D), Hospital Anxiety and Depression Scale
(HADS), history of falls, fractures and HRU were investigated
through a telephone survey. Comparisons needed chi-square
tests, analysis of variance, and multivariate regression models.
RESULTS: Mean age of AMD patients was 79 and 64% were
female. Comparisons were adjusted for age, gender, and comor-
bid diseases. The mean (95% CI) NEI VFQ overall scale scores
was 44.4 (36.2, 52.6) in AMD patients, vs 91.8 (86.2, 97.5) for
controls p < 0.0001. AMD patients also differed on the HADS
scales: anxiety score: 8.5 (6.3, 10.8) vs. 5.1 (3.5, 6.7),
p = 0.0005; depression scores: 7.1 (5.1, 9.1) vs. 2.9 (1.5, 4.4),
p < 0.0001. A negative trend is observed on EQ-5D: 0.6 (0.5,
0.7) vs. 0.7 (0.6, 0.8), p = 0.0893. In addition, 11.5% of AMD
patients fell in the past 12 months vs 3.3% of controls,
p = 0.053. Furthermore 41.4% of the AMD patients received
assistance for daily activities vs 6.5% of controls, p < 0.0001.
CONCLUSION: Bilateral AMD patients in France reported sub-
stantially worse QOL, poorer vision-related functioning, and
more anxiety and depression symptoms compared with a control
group.
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OBJECTIVES: To adapt the Glaucoma Symptom Scale (GSS) to
Iberian Spanish, and to study the psychometric properties of the
new version. The GSS scale is composed by 10 items, measuring
impact of glaucoma symptoms. Items should be answered for
both eyes. METHODS: An expert panel composed of two oph-
thalmologists, one gerontologist, two methodologists and one
pharma-economist supervised the adaptation procedure. Two
samples were recruited, one composed by 16 patients used to
check comprehension of the ﬁrst version, and 100 sample used
to obtain psychometric estimates. Patients were recruited in
Madrid, Zaragoza and Barcelona. Psychometric properties were
assessed for each eye and for between eyes average scores. Item
analysis, exploratory factor analysis and reliability estimates
were obtained. RESULTS: Patients ranged from 57 to 89 years
old and 50% were female. Symptoms were selected by 30% to
51% of patients, with a slight lower (p = 0.09) presence of symp-
toms in the right eye (mean = 4.3, SD = 3) than in the left eye
(mean = 4.6, SD = 3.1). A high correlation in the number of
symptoms present in each eye was found (r = 0.84, p < 0.001).
The scale could match the original proposed structure of a
functional domain and a non visual ocular symptom domain,
explaining 53% of available variance, but two items “tearing”
and “halos around lights” don’t exhibit high loadings. A three
dimensional structure would exhibit a better ﬁt. Dimensions
show mild correlations (0.14–0.36). Internal consistency is good
(Cronbach alpha = 0.82) and correlation between odd and even
items is moderate 0.653. Content validity was ensured by the
original researchers work. CONCLUSION: The Spanish version
of the GSS questionnaire shows acceptable psychometric prop-
erties. The two dimensional solution is supported although it
does not explain properly all symptoms. Further validity evi-
dences should be collected with special concern on screening
properties and responsiveness should be also evaluated.
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OBJECTIVES: The SF-36, a generic health-related quality of life
measure, comprises 8 domains (Ware 2000) for which physical
and mental component summaries (PCS and MCS) can be
derived (Ware, Kosinski 2001). Until now, no MID for the SF-36
domains and summary scores have been reported for patients
with active Crohn’s disease (CD). Our aims were to determine
the MID for SF-36 using data from the PRECiSE 1 trial (Sand-
born et al. 2006), and to use these MIDs for the interpretation of
results from the PRECiSE 2 trial investigating certolizumab pegol
maintenance treatment (Schreiber et al. 2005). METHODS:
SF-36 MIDs were estimated by anchor-based methods using
known meaningful changes in reference measures (Inﬂammatory
Bowel Disease Questionnaire [IBDQ] and CD Activity Index
[CDAI]). The a priori approach was to select the SF-36 MID
according to the most correlated anchor. Agreement of the
anchor-derived MIDs with results obtained using Standardised
Effect Sizes, Standard Errors of Measurement and Standard
Errors of the Difference was also evaluated. RESULTS: The two
anchors gave similar values of meaningful changes. The IBDQ,
which correlated most closely to SF-36 score changes, was
selected to derive the SF-36 MIDs. Results obtained with other
methods were in agreement with these derived MIDs and were
representative of small to moderate changes (effect sizes ranging
from 0.2 to 0.5). Based on these calculations, it was shown that
a signiﬁcantly higher proportion of patients showed a clinically
meaningful response in the SF-36 PCS and MCS after certoli-
zumab pegol maintenance treatment compared to patients
receiving placebo. CONCLUSION: A multi-faceted approach to
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